Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:


Respiratory-Pacing Device Found Beneficial in Heart Failure


Outcomes of two studies presented at the Heart Failure Society of America suggest a promising non-invasive device-based treatment approach

Heart failure patients witnessed a significant improvement in disease symptoms and markers of the underlying pathology using an experimental non-invasive treatment device, inTone™, according to two studies presented this week at the 2003 Heart Failure Society of America annual conference in Las Vegas.

"We have long known about the beneficial effects of respiratory-pacing on the cardiovascular system," Said Dr. Gianfranco Parati, Professor of Medicine and Director of the Second Cardiology Unit, S.Luca Hospital, Istituto Auxologico Italiano, Milan, Italy and an investigator of one of the studies. "Having a device which delivers such a therapy in the comfort of the patients’ home is very promising. With just 15-minutes session twice a day, we have seen in our pilot study that patients’ ejection fraction (EF), pulmonary artery pressure (PAP) and performance at the 6-minutes walk test improved significantly. In addition, we have seen a significant improvement in patients’ quality of life (QOL) as reflected by a formal QOL questionnaire and by patients attesting to their ability to climb stairs, carry groceries and breathe easier throughout the day and night. Personally, I was most impressed by the fact that patients were reluctant to return the devices at the end of the study."

"Since the FDA clearance of our first therapeutic device, RESPeRATE® to lower blood pressure, we are constantly perusing additional applications for our Low-Frequency Respiratory-Pacing technology" said Erez Gavish, CEO of InterCure, inTone’s & RESPeRATE’s manufacturer. "We are encouraged by the promising outcomes of these first two heart failure studies and are looking forward to study inTone further in a pivotal trial setting in the near future."

For reprints of the abstracts and posters as well as additional information about inTone or RESPeRATE see or call Tom Kirwan at (201) 720-7750, ext. 7136.

About InterCure Ltd. & RESPeRATE™

InterCure ( is a medical device company pioneering the application of respiratory-pacing technology for the treatment of hypertension and heart failure. Following six successful clinical trials, RESPeRATE™ (, InterCure’s first product, became the only FDA-cleared, non-drug medical device indicated for the adjunctive treatment of hypertension. InterCure heart failure product, InTone™ has successfully completed phase 2a efficacy clinical trials and is expected to be launched after it completes the regulatory approval process.

Tom Kirwan | InterCure Ltd
Further information:

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Space observation with radar to secure Germany's space infrastructure

Satellites in near-Earth orbit are at risk due to the steady increase in space debris. But their mission in the areas of telecommunications, navigation or weather forecasts is essential for society. Fraunhofer FHR therefore develops radar-based systems which allow the detection, tracking and cataloging of even the smallest particles of debris. Satellite operators who have access to our data are in a better position to plan evasive maneuvers and prevent destructive collisions. From April, 25-29 2018, Fraunhofer FHR and its partners will exhibit the complementary radar systems TIRA and GESTRA as well as the latest radar techniques for space observation across three stands at the ILA Berlin.

The "traffic situation" in space is very tense: the Earth is currently being orbited not only by countless satellites but also by a large volume of space...

Im Focus: Researchers Discover New Anti-Cancer Protein

An international team of researchers has discovered a new anti-cancer protein. The protein, called LHPP, prevents the uncontrolled proliferation of cancer cells in the liver. The researchers led by Prof. Michael N. Hall from the Biozentrum, University of Basel, report in “Nature” that LHPP can also serve as a biomarker for the diagnosis and prognosis of liver cancer.

The incidence of liver cancer, also known as hepatocellular carcinoma, is steadily increasing. In the last twenty years, the number of cases has almost doubled...

Im Focus: Researchers at Fraunhofer monitor re-entry of Chinese space station Tiangong-1

In just a few weeks from now, the Chinese space station Tiangong-1 will re-enter the Earth's atmosphere where it will to a large extent burn up. It is possible that some debris will reach the Earth's surface. Tiangong-1 is orbiting the Earth uncontrolled at a speed of approx. 29,000 km/h.Currently the prognosis relating to the time of impact currently lies within a window of several days. The scientists at Fraunhofer FHR have already been monitoring Tiangong-1 for a number of weeks with their TIRA system, one of the most powerful space observation radars in the world, with a view to supporting the German Space Situational Awareness Center and the ESA with their re-entry forecasts.

Following the loss of radio contact with Tiangong-1 in 2016 and due to the low orbital height, it is now inevitable that the Chinese space station will...

Im Focus: Alliance „OLED Licht Forum“ – Key partner for OLED lighting solutions

Fraunhofer Institute for Organic Electronics, Electron Beam and Plasma Technology FEP, provider of research and development services for OLED lighting solutions, announces the founding of the “OLED Licht Forum” and presents latest OLED design and lighting solutions during light+building, from March 18th – 23rd, 2018 in Frankfurt a.M./Germany, at booth no. F91 in Hall 4.0.

They are united in their passion for OLED (organic light emitting diodes) lighting with all of its unique facets and application possibilities. Thus experts in...

Im Focus: Mars' oceans formed early, possibly aided by massive volcanic eruptions

Oceans formed before Tharsis and evolved together, shaping climate history of Mars

A new scenario seeking to explain how Mars' putative oceans came and went over the last 4 billion years implies that the oceans formed several hundred million...

All Focus news of the innovation-report >>>



Industry & Economy
Event News

New solar solutions for sustainable buildings and cities

23.03.2018 | Event News

Virtual reality conference comes to Reutlingen

19.03.2018 | Event News

Ultrafast Wireless and Chip Design at the DATE Conference in Dresden

16.03.2018 | Event News

Latest News

For graphite pellets, just add elbow grease

23.03.2018 | Materials Sciences

Unique communication strategy discovered in stem cell pathway controlling plant growth

23.03.2018 | Agricultural and Forestry Science

Sharpening the X-ray view of the nanocosm

23.03.2018 | Physics and Astronomy

Science & Research
Overview of more VideoLinks >>>